Anatomical, physiological and inflammatory characterization of nonculprit vessels in patients undergoing primary PCI for ST-elevation myocardial infarction in the presence of multivessel disease: Rationale and design of the PICNIC study - 03/12/25
ABSTRACT |
Background |
Up to 50% of patients presenting with ST-elevation myocardial infarction (STEMI) have multivessel coronary artery disease (CAD). Randomized trials suggest that complete revascularization improves outcomes, but the mechanism and identification of patients who benefit remain unclear. This study aims to assess the association between blood and coronary imaging biomarkers and clinical events, to identify patient-, vessel-, and lesion-specific risk in STEMI patients with bystander disease.
Method |
PICNIC is a multicenter, international, prospective, observational study enrolling 320 patients with STEMI and multivessel CAD undergoing primary PCI of the culprit vessel without complete revascularization. Participants will undergo blood sampling for inflammatory markers and coronary CT angiography (CTCA) to assess: (1) plaque burden and morphology, (2) artificial intelligence-enabled fractional flow reserve derived from CTCA (FFR CT ) analysis of plaque and hemodynamic features, and (3) fat attenuation index (FAI) to evaluate perivascular inflammation.
The primary analysis will evaluate the association between a composite 24-month clinical endpoint (including all-cause mortality, myocardial infarction, ischemia-driven revascularization as first layer and cardiac arrest, heart failure, stroke, and ventricular tachyarrhythmia (second layer)) and: (1) serum inflammatory markers, and (2) anatomical and physiological characteristics of non–infarct-related arteries (NIRA) assessed by CTCA, FFR CT , and FAI. Statistical and machine learning methods will be applied to determine which combinations of clinical, imaging, and biomarker data best predict patient-, vessel-, and lesion-specific risk.
Conclusion |
PICNIC will characterize the anatomical, physiological, and inflammatory features of NIRA lesions in STEMI patients treated with culprit-only PCI in order to develop an AI-based risk prediction model. If such a model is successful it could be used to inform personalized revascularization strategies.
Le texte complet de cet article est disponible en PDF.Plan
Vol 292
Article 107298- février 2026 Retour au numéro
Article précédent
- PRospective evaluation of the European Society of Cardiology 0/1h-algorithm`s safety and efficacy for triage of patients with suspected myocardial infarction (PRESC1SE-MI): Rationale and design of a prospective international multicenter stepped-wedge cluster randomized controlled trial
- Jasper Boeddinghaus, Paolo Bima, Luca Crisanti, Dagmar I Keller, Ksenija Slankamenac, Michael Christ, Philipp Schuetz, Andrea Wiencierz, Ivo Strebel, Julia Reinhardt, Iryna Vyshnevska, Tzu-Ying Tsao, Felix Mahfoud, Maria Pia Ruggieri, Stephan Steuer, Òscar Miró, Veli-Pekka Harjola, Fulvio Morello, Peiman Nazerian, Dominik Roth, José Luis Zamorano, Deborah Erica Gannon, Jason Pott, Mohammed OA Abubakr, Hyun Suk Yang, Joe Young, Richina Bicette, Andreea Cuculici, Héctor Bueno, Juan Sanchis, Christian Mueller, for the PRESC1SE-MI investigators, Doris Eis, Stefan Venturini, Sebastian Haubitz, Angelika Hammerer-Lercher, Laurent Haegeli, Martin Schläpfer, Simone Weisskopf, Gemma Martínez-Nadal, Beatriz López-Barbeito, Johan Lassus, Kimmo Suojanen, Tomi Mäkiaho, Enrico Lupia, Silvia Tarditi, Giulia Labarile, Giuliano De Stefano, Eduardo Del Gais, Gianni Mecocci, Maximilian Niederer, Larissa Bernert, Paloma Remior Perez, Marcelo Sanmartín Fernánd, Clemencia de Rueda Panadero, Vanesa Santos Polo, Virginia Gehrke, Sharyl Dwyer, Julie Goofruit, Ben Bloom, Raine Astin-Chamberlain, Noemi Caponi, Emily Campell, Fatma Mohammed, Nimca Omer, Alison Quinn, Jaqueline Sear, Grace Tunesi, Cristina Thiebaud, Karen Hopkins, Katie Morgan, Kyeong Ryong Lee, Mina Hur, Frank W. Peacock, Phong Huynh, Adriana Covaliov, Ovidiu Chioncel, Gabriele Valli, Francesca De Marco, M. Lorena Castro Arias, Rodrigo Pacheco Puig, Guillermo Moreno, Berk Mehmet Feyzi, Jorge Velez Garcia, Agustín Fernández-Cisnal, Jose Noceda, Aura Winterhalder, Beate Hartmann, Lu Cheng, Laura Pedrini, Maximillian Mais, Marie Therese Niggemann, Luca Koechlin, Pedro Lopez-Ayala, David Santer, Tamar S. Muench-Gerber, Ana Yufera Sanchez, Anna H. Porwit, Nicholas L. Mills, David Conen, Christopher B. Granger, John Parissis
- Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trial
- Gilles Montalescot, Leonardo Bolognese, Stanislaw Bartus, Angel Cequier-Fillat, Holger Thiele, François Mach, J. Wouter Jukema, Emile Ferrari, Géraud Souteyrand, Claire Bouleti, Grégoire Range, Marco Chioccioli, Andréa Picchi, Laure Batias-Moreau, Giovanni Esposito, Nassim Braik, Nassim Redjimi, Benjamin Duband, Paul Guedeney, Michel Zeitouni, Karine Brochard, Johanne Silvain, Eric Vicaut, on behalf of the AMUNDSEN investigators of the ACTION Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?